Codexis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Codexis, Inc. on October 8, 2015. The report addresses a specific corporate event occurring in the third quarter of 2015 regarding the company's strategic partnership with GlaxoSmithKline.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a non-financial operational milestone rather than periodic financial results.
Material Changes
The primary material event reported is the completion of Wave 2 of the transfer of Codexis's CodeEvolver protein engineering platform technology to GlaxoSmithKline. This transfer was finalized in the third quarter of 2015.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors. It references a press release (Exhibit 99.1) for the full details of the announcement but does not include the text of that release within this summary.
Investor Verification Checklist
- Verify the specific terms and financial implications of the Wave 2 technology transfer by reviewing the attached press release (Exhibit 99.1).
- Confirm the status of any remaining waves in the technology transfer agreement with GlaxoSmithKline.
- Review the company's most recent quarterly report (10-Q) for the third quarter of 2015 to assess the financial impact of this milestone.